Literature DB >> 8706344

Predominance of a type 2 intratumoural immune response in fresh tumour-infiltrating lymphocytes from human gliomas.

E Roussel1, M C Gingras, E A Grimm, J M Bruner, R P Moser.   

Abstract

Increasing evidence suggests the existence of polarized human T cell responses described as Th1-type (promoting cell-mediated immunity) and Th2-type (promoting humoral immunity), characterized by a dominant production of either interferon-gamma (IFN-gamma) or IL-4, respectively. Little is known about the intratumoural activation of infiltrating lymphocytes (TIL) in human gliomas. Therefore, we assessed fresh TIL at cellular and molecular levels to find out if they were activated and polarized into a type 1 or 2 immune response. Flow cytometry analysis of TIL revealed that the major subset was made of T lymphocytes. Double labelling with alpha-CD3 and adhesion/ activation markers revealed T cell subsets expressing CD49a, CD49b, CD54, and CD15, some of which were almost absent in autologous T peripheral blood lymphocytes (T-PBL). Furthermore, the proportions of T-TIL expressing CD56, CD65, or CD25 were several-fold higher than in T-PBL. Intratumoural functional activation of TIL was tested by semiquantitative assessment in relative units (RU) of lymphokine gene activation with mRNA reverse transcriptase-polymerase chain reaction (RT-PCR). All TIL populations except one significantly expressed IL-4 1 to 2 logs of RU above healthy PBL baseline. Similarly, all patients expressed granulocyte-macrophage colony-stimulating factor (GM-CSF) in a range comparable to IL-4. However, most TIL populations did not express IFN-gamma, IL-2, and tumour necrosis factor-beta (TNF-beta) at higher levels than healthy normal PBL. The increase proportion of T cells expressing activation markers and the consistent detection of significant IL-4 and GM-CSF lymphokine gene activation in TIL populations suggested a predominant type 2 intratumoural immune response that does not promote cell-mediated tumouricidal activity and may contribute to the inefficiency of the antiglioma immune response.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706344      PMCID: PMC2200505          DOI: 10.1046/j.1365-2249.1996.d01-753.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  "...those left behind." Biology and oncology of invasive glioma cells.

Authors:  M E Berens; A Giese
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

Review 3.  Immunotherapy for primary brain tumors: no longer a matter of privilege.

Authors:  Peter E Fecci; Amy B Heimberger; John H Sampson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

4.  Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.

Authors:  Gary Kohanbash; Diego A Carrera; Shruti Shrivastav; Brian J Ahn; Naznin Jahan; Tali Mazor; Zinal S Chheda; Kira M Downey; Payal B Watchmaker; Casey Beppler; Rolf Warta; Nduka A Amankulor; Christel Herold-Mende; Joseph F Costello; Hideho Okada
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

5.  Oral Squamous Carcinoma Cells Express B7-H1 and B7-DC Receptors in Vivo.

Authors:  Sabine Groeger; H P Howaldt; H Raifer; S Gattenloehner; T Chakraborty; J Meyle
Journal:  Pathol Oncol Res       Date:  2016-08-08       Impact factor: 3.201

6.  Tumor-infiltrating lymphocytes (TILs) from patients with glioma.

Authors:  Zhenjiang Liu; Qingda Meng; Jiri Bartek; Thomas Poiret; Oscar Persson; Lalit Rane; Elena Rangelova; Christopher Illies; Inti Harvey Peredo; Xiaohua Luo; Martin Vijayakumar Rao; Rebecca Axelsson Robertson; Ernest Dodoo; Markus Maeurer
Journal:  Oncoimmunology       Date:  2016-11-29       Impact factor: 8.110

Review 7.  Embracing rejection: Immunologic trends in brain metastasis.

Authors:  S Harrison Farber; Vadim Tsvankin; Jessica L Narloch; Grace J Kim; April K S Salama; Gordana Vlahovic; Kimberly L Blackwell; John P Kirkpatrick; Peter E Fecci
Journal:  Oncoimmunology       Date:  2016-04-11       Impact factor: 8.110

8.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.

Authors:  S Farzana Hussain; David Yang; Dima Suki; Kenneth Aldape; Elizabeth Grimm; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2006-06-14       Impact factor: 12.300

9.  miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy.

Authors:  Kotaro Sasaki; Gary Kohanbash; Aki Hoji; Ryo Ueda; Heather A McDonald; Todd A Reinhart; Jeremy Martinson; Michael T Lotze; Francesco M Marincola; Ena Wang; Mitsugu Fujita; Hideho Okada
Journal:  J Transl Med       Date:  2010-02-18       Impact factor: 5.531

Review 10.  Challenges in clinical design of immunotherapy trials for malignant glioma.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.